Prot #ISA101b-HN-01-17: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)

Project: Research project

Project Details

StatusActive
Effective start/end date4/22/19 → 4/22/25

Funding

  • Syneos Health, Inc. (Prot #ISA101b-HN-01-17)
  • ISA Therapeutics B.V. (Prot #ISA101b-HN-01-17)